SION
Sionna Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-41/100
Last price
4.75
▼ 0.10 (2.06%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.75
Prev close
4.85
Day high
4.88
Day low
4.52
Volume
1.26M
Market cap
$214.46M
P/E (TTM)
—
52W range
4.01 – 54.97
Day trading desk
Gap from prior close
-2.06%
Prior close 4.85
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
4.75 – 4.75
Position in range
—
—
ATR (14D)
0.44
9.32% of price
Prior day high
4.96
PDH
Prior day low
4.63
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 2.17M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.77%
-9.7%
1M
-33.84%
-35.0%
3M
-89.20%
-93.7%
6M
-87.08%
-105.3%
YTD
-88.45%
-102.7%
1Y
-84.17%
-100.6%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SION open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-5.26M
Net selling
Buy transactions
3
322.84K shares
Sell transactions
13
5.58M shares
Net transactions
+16
Buys less sells
Sell : buy shares
17.3 : 1
Heavily one-sided
Insider-held shares
3.56M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 17, 26 | RA CAPITAL HEALTHCARE FUND,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 3.45M | $21.84M | Indirect |
| Sep 17, 26 | CLOONAN MICHAEL Chief Executive Officer |
STOCK | 218.05K | $0 | Direct |
| Sep 17, 26 | RIDLOFF ELENA Chairman of the Board |
STOCK | 94.54K | $0 | Direct |
| Jul 7, 26 | THOMPSON PETER A Director |
SELL | 85.92K | $3.85M | Indirect |
| Jul 7, 26 | ORBIMED ADVISORS, L.L.C. Unknown |
SELL | 85.92K | $3.85M | Indirect |
| Jul 6, 26 | FITZPATRICK JENNIFER R Officer |
CONVERSION | 10.25K | $62.63K | Direct |
| Jul 6, 26 | FITZPATRICK JENNIFER R Officer |
SELL | 10.25K | $446.86K | Direct |
| Jun 30, 26 | THOMPSON PETER A Director |
SELL | 115.84K | $5.27M | Indirect |
| Jun 30, 26 | ORBIMED ADVISORS, L.L.C. Director |
SELL | 115.84K | $5.27M | Indirect |
| May 27, 26 | THOMPSON PETER A Director |
SELL | 101 | $4.49K | Indirect |
| May 11, 26 | THOMPSON PETER A Director |
SELL | 292.95K | $13.36M | Indirect |
| May 11, 26 | ORBIMED ADVISORS, L.L.C. Unknown |
SELL | 292.95K | $13.36M | Indirect |
| Apr 17, 26 | THOMPSON PETER A Director |
SELL | 55.34K | $2.47M | Indirect |
| Apr 17, 26 | ORBIMED ADVISORS, L.L.C. Unknown |
SELL | 55.34K | $2.47M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ATLAS VENTURE FUND XI L.P |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
CLOONAN MICHAEL |
Chief Executive Officer | 765.39K | Stock Award(Grant) |
FITZPATRICK JENNIFER R |
Officer | 0 | Conversion of Exercise of derivative security |
ORBIMED ADVISORS, L.L.C. |
Unknown | — | Sale |
RA CAPITAL HEALTHCARE FUND,L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
RIDLOFF ELENA |
Chairman of the Board | 133.07K | Stock Award(Grant) |
THOMPSON PETER A |
Director | — | Sale |
TPG GP A LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
TPG GP A, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$214.46M
Enterprise value$11.80M
Revenue (TTM)—
Gross profit—
EBITDA$-108.84M
Net income$-97.38M
EPS (TTM)$-2.16
Free cash flow$-45.44M
Total cash$211.03M
Total debt$8.07M
Book value / share$5.89
Shares outstanding45.15M
Float20.47M
Short % of float14.23%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.13
PEG ratio—
Price / sales—
Price / book0.81
EV / revenue—
EV / EBITDA-0.11
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-32.34%
Return on assets-21.54%
Debt / equity3.04
Current ratio20.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $60.26M | $57.29M | $40.63M | $34.60M | +5.2% |
| Selling, general & admin | $28.72M | $13.27M | $9.71M | $6.77M | +116.5% |
| Total operating expense | $88.98M | $70.56M | $50.33M | $41.37M | +26.1% |
| Operating income | -$88.98M | -$70.56M | -$50.33M | -$41.37M | -26.1% |
| Net interest income | $13.29M | $8.17M | $2.77M | $1.13M | +62.7% |
| Pre-tax income | -$75.27M | -$61.69M | -$47.26M | -$40.24M | -22.0% |
| Net income | -$75.27M | -$61.69M | -$47.26M | -$40.24M | -22.0% |
| Net income to common | -$75.27M | -$61.69M | -$47.26M | -$40.24M | -22.0% |
| Basic EPS | -1.88 | -1.45 | -1.70 | -2.32 | -29.4% |
| Diluted EPS | -1.88 | -1.45 | -1.70 | -2.32 | -29.4% |
| EBIT | -$88.98M | -$70.56M | -$50.33M | -$41.37M | -26.1% |
| EBITDA | -$88.33M | -$69.89M | -$49.75M | -$41.25M | -26.4% |
| Basic shares | 39.96M | 42.44M | 27.80M | 17.33M | -5.8% |
| Diluted shares | 39.96M | 42.44M | 27.80M | 17.33M | -5.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $58.45M | $37.79M | $38.52M | $54.84M | +54.7% |
| Cash & short-term investments | $235.88M | $147.54M | $38.52M | $82.61M | +59.9% |
| Total current assets | $241.42M | $150.99M | $39.21M | $83.83M | +59.9% |
| Property, plant & equipment | $9.15M | $10.30M | $11.73M | $2.57M | -11.1% |
| Total assets | $325.95M | $185.75M | $51.95M | $87.37M | +75.5% |
| Total current liabilities | $11.71M | $10.42M | $8.04M | $8.25M | +12.4% |
| Total debt | $8.68M | $9.75M | $10.48M | $0 | -11.0% |
| Total liabilities | $19.12M | $349.46M | $166.83M | $157.29M | -94.5% |
| Retained earnings | -$256.35M | -$181.09M | -$119.40M | -$72.14M | -41.6% |
| Shareholder equity | $306.83M | -$163.71M | -$114.88M | -$69.92M | +287.4% |
| Working capital | $229.71M | $140.57M | $31.17M | $75.58M | +63.4% |
| Net tangible assets | $306.83M | -$163.71M | -$114.88M | -$69.92M | +287.4% |
| Shares issued | 44.72M | 42.44M | 42.44M | 42.44M | +5.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$75.27M | -$61.69M | -$47.26M | -$40.24M | -22.0% |
| Depreciation & amortisation | $647.00K | $668.00K | $583.00K | $122.00K | -3.1% |
| Stock-based compensation | $12.07M | $3.71M | $2.26M | $1.69M | +225.4% |
| Change in working capital | -$2.65M | -$3.08M | -$783.00K | $2.76M | +13.8% |
| Operating cash flow | -$66.30M | -$52.79M | -$43.70M | -$36.07M | -25.6% |
| Capital expenditure | -$377.00K | -$27.00K | -$1.12M | -$1.87M | -1,296.3% |
| Investing cash flow | -$118.75M | -$126.91M | $27.35M | -$29.26M | +6.4% |
| Financing cash flow | $205.71M | $178.97M | $31.00K | $110.86M | +14.9% |
| Free cash flow | -$66.67M | -$52.81M | -$44.81M | -$37.94M | -26.2% |
| End cash position | $59.41M | $38.75M | $39.48M | $55.80M | +53.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $21.86M | $18.96M | $15.17M | $16.04M | $15.38M | +15.3% |
| Selling, general & admin | $9.97M | $10.15M | $9.87M | $7.24M | $6.04M | -1.7% |
| Total operating expense | $32.47M | $29.60M | $23.61M | $23.80M | $21.91M | +9.7% |
| Operating income | -$32.47M | -$29.60M | -$23.61M | -$23.80M | -$21.91M | -9.7% |
| Net interest income | $2.59M | $2.82M | $3.17M | $3.46M | $3.67M | -8.3% |
| Pre-tax income | -$29.89M | -$26.78M | -$20.44M | -$20.28M | -$18.07M | -11.6% |
| Net income | -$29.89M | -$26.78M | -$20.44M | -$20.28M | -$18.07M | -11.6% |
| Net income to common | -$29.89M | -$26.78M | -$20.44M | -$20.28M | -$18.07M | -11.6% |
| Basic EPS | -0.66 | -0.60 | -0.46 | -0.46 | -0.41 | -10.0% |
| Diluted EPS | -0.66 | -0.60 | -0.46 | -0.46 | -0.41 | -10.0% |
| EBIT | -$32.47M | -$29.60M | -$23.61M | -$23.80M | -$21.91M | -9.7% |
| EBITDA | -$31.84M | -$29.11M | -$23.46M | -$23.29M | -$21.43M | -9.4% |
| Basic shares | 45.15M | 44.92M | 44.64M | 44.26M | 44.12M | +0.5% |
| Diluted shares | 45.15M | 44.92M | 44.64M | 44.26M | 44.12M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.32M | $63.32M | $58.45M | $50.83M | $40.98M | -0.0% |
| Cash & short-term investments | $211.03M | $216.15M | $235.88M | $248.33M | $262.57M | -2.4% |
| Total current assets | $216.13M | $220.96M | $241.42M | $252.33M | $266.75M | -2.2% |
| Property, plant & equipment | $8.34M | $8.75M | $9.15M | $9.31M | $9.64M | -4.7% |
| Total assets | $283.25M | $305.04M | $325.95M | $339.27M | $352.05M | -7.1% |
| Total current liabilities | $10.78M | $9.78M | $11.71M | $9.85M | $7.55M | +10.3% |
| Total debt | $8.07M | $8.38M | $8.68M | $8.97M | $9.24M | -3.7% |
| Total liabilities | $17.47M | $16.83M | $19.12M | $17.60M | $15.62M | +3.8% |
| Retained earnings | -$313.02M | -$283.13M | -$256.35M | -$235.91M | -$215.64M | -10.6% |
| Shareholder equity | $265.77M | $288.21M | $306.83M | $321.67M | $336.43M | -7.8% |
| Working capital | $205.35M | $211.18M | $229.71M | $242.48M | $259.20M | -2.8% |
| Net tangible assets | $265.77M | $288.21M | $306.83M | $321.67M | $336.43M | -7.8% |
| Shares issued | 45.16M | 45.08M | 44.72M | 44.46M | 44.13M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$29.89M | -$26.78M | -$20.44M | -$20.28M | -$18.07M | — | -11.6% |
| Depreciation & amortisation | $155.00K | $154.00K | $152.00K | $189.00K | $147.00K | — | +0.6% |
| Stock-based compensation | $6.84M | $6.55M | $3.83M | $3.31M | $2.84M | — | +4.4% |
| Change in working capital | $334.00K | -$2.06M | -$302.00K | $1.90M | -$2.40M | — | +116.2% |
| Operating cash flow | -$22.22M | -$21.84M | -$16.63M | -$15.23M | -$18.15M | — | -1.7% |
| Capital expenditure | — | — | -$204.00K | -$87.00K | — | -$86.00K | — |
| Investing cash flow | $21.47M | $24.82M | $22.59M | $23.10M | -$23.25M | — | -13.5% |
| Financing cash flow | $749.00K | $1.89M | $1.66M | $1.97M | -$312.00K | — | -60.4% |
| Free cash flow | -$22.22M | -$21.84M | -$16.83M | -$15.32M | -$18.15M | — | -1.7% |
| End cash position | $64.28M | $64.29M | $59.41M | $51.79M | $41.95M | — | -0.0% |
Options analytics
Put / call volume
5.73
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-47.4% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
107
Contracts, this expiry
Put volume
613
Contracts, this expiry
Heaviest call OI
22.50
1 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.65 | -0.66 | -2.0% |
| Mar 2026 | -0.50 | -0.60 | -19.1% |
| Dec 2025 | -0.54 | -0.46 | +14.0% |
| Sep 2025 | -0.48 | -0.46 | +3.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.68 | 8 | $0 | 0.0% |
| Next quarter | -0.55 | 8 | $0 | 0.0% |
| Current year | -2.45 | 10 | $0 | 0.0% |
| Next year | -2.23 | 10 | $0 | 0.0% |
Analyst targets & ownership
Mean target$21.00
High target$63.00
Low target$5.00
Implied upside342.11%
Analyst count7
ConsensusHOLD
Strong buy / Buy0 / 2
Hold10
Sell / Strong sell0 / 0
Held by insiders7.88%
Held by institutions99.24%
Institutions holding203
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.11
-7.06% from price
SMA 20
6.07
-21.75% from price
SMA 50
13.65
-65.21% from price
SMA 100
27.40
-82.67% from price
SMA 200
33.41
-85.78% from price
EMA 12
5.38
-11.69% from price
EMA 26
7.49
-36.55% from price
EMA 50
13.35
-64.43% from price
RSI (14)
26.5
Oversold
MACD (12,26,9)
-2.11
Hist 0.54
ATR (14)
0.44
9.32% of price
Realised vol 30D
105.4%
Annualised
Bollinger upper
8.30
20, 2σ
Bollinger lower
3.84
20, 2σ
50 / 200 cross
Death
13.65 vs 33.41
Trend bias
Below 200
-85.78%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.10
More volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
105.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-91.2%
Peak to trough
Max drawdown 5Y
-91.2%
Peak to trough
ATR 14
0.44
9.32% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.97M
Prior 4.25M
Change vs prior
-6.6%
Shorts covering
% of float
14.23%
Elevated
% of shares out
8.77%
Against total outstanding
Days to cover
2.7
Liquid
Float
20.47M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | Wedbush | MAINTAINED | Neutral | Neutral |
| Aug 11, 26 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Aug 11, 26 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Aug 10, 26 | BTIG | DOWNGRADE | Buy | Neutral |
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 26, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 20, 26 | Freedom Broker | DOWNGRADE | Buy | Hold |
| May 18, 26 | Stifel | MAINTAINED | Buy | Buy |
| May 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 5, 26 | Wedbush | INITIATED | — | Outperform |
| Apr 28, 26 | Jones Trading | MAINTAINED | Buy | Buy |
| Apr 27, 26 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEFA14A · 2026-04-27
Offering Registrations
S-3ASR · 2026-03-02
Corporate Changes & Voting Matters
8-K · 2025-11-05
Headlines
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
Insider Monkey · 20d ago
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Zacks · 21d ago
FDA clears first generic radioligand drug; Sionna turns to layoffs
BioPharma Dive · 22d ago
Wedbush Raises Price Target on Sionna Therapeutics to $6 From $5, Keeps Neutral Rating
MT Newswires · 22d ago
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
GlobeNewswire · 23d ago
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Motley Fool · 48d ago
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
Simply Wall St. · 55d ago
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
Simply Wall St. · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.